Calliditas Therapeutics AB: Change in financial calendar

Rhea-AI Summary

Calliditas Therapeutics AB (Nasdaq: CALT) has announced a change in its financial calendar, moving the publication of its interim report for Q1 2021 from May 13, 2021, to May 18, 2021. This shift is due to the overlap with Ascension Day. Calliditas is developing Nefecon, an oral formulation of budesonide for treating IgA nephropathy, targeting a high unmet medical need. The company is undertaking a global Phase 3 study and aims to commercialize the treatment in the U.S.

Positive

• Calliditas is progressing with a global Phase 3 study for Nefecon, targeting IgA nephropathy.
• The shift in the publication date provides clarity to investors, avoiding a conflict with a public holiday.

Negative

• The change in financial calendar may cause temporary uncertainty among investors regarding financial disclosures.

STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announces today that the Board has decided that the interim report for the first quarter 2021 will be published on May 18, 2021. The previously planned date for publication was May 13, 2021, which is the Ascension Day.

The information was submitted for publication at 14:30 CET on April 27, 2021, by the below contact person.

For further information, please contact:

Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com

About Calliditas

Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/change-in-financial-calendar,c3334531

The following files are available for download:

https://mb.cision.com/Main/16574/3334531/1408163.pdf

Change in financial calendar EN

View original content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-ab-change-in-financial-calendar-301277946.html

SOURCE Calliditas Therapeutics

FAQ

When will Calliditas publish its Q1 2021 interim report?

Calliditas will publish its Q1 2021 interim report on May 18, 2021.

Why was the Q1 2021 report date changed for Calliditas?

The report date was changed due to the original date, May 13, 2021, coinciding with Ascension Day.

What is Nefecon, the product developed by Calliditas?

Nefecon is a proprietary oral formulation of budesonide aimed at treating IgA nephropathy.

What is the significance of the Phase 3 study for Calliditas?

The Phase 3 study is crucial for the development and potential commercialization of Nefecon in the U.S.